Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Healthcare may not lead the next market rally, but current levels offer compelling risk/reward for contrarian investors ...

The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

A second magnificent ultra-high-yield dividend stock that's begging to be bought in November is pharmaceutical titan Pfizer ( ...

Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same time frame last year. That came after vaccine sales rose the first two ...

You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

S&P 500 gained 1.5 per cent, while the Nasdaq Composite gained 2.26 per cent, to 23,524.82. Read more at straitstimes.com.

Days after the Supreme Court appeared skeptical of the legal backing for many of his tariffs, the president on social media Sunday lauded the revenue they have brought in and said the government would ...

Donald Trump engages in ad hoc agreements with individual companies and governments to expand his power. Some observers have described these actions as a new “economic nationalism”—but that term fails ...

The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...